The goal of this study was to explore mechanisms that mediate hypersecretion of LH and progressive loss of cyclicity in female sheep exposed during fetal life to excess testosterone. Our working hypothesis was that prenatal testosterone excess, by its androgenic action, amplifies GnRH-induced LH (but not FSH) secretion and, thus, hypersecretion of LH in adulthood, and that this results from altered developmental gene expression of GnRH and estradiol (E 2 ) receptors, gonadotropin subunits, and paracrine factors that differentially regulate LH and FSH synthesis. We observed that, relative to controls, females exposed during fetal life to excess testosterone, as well as the nor-aromatizable androgen dihydrotestosterone, exhibited enhanced LH but not FSH responses to intermittent delivery of GnRH boluses under conditions in which endogenous LH (GnRH) pulses were suppressed. Luteinizing hormone hypersecretion was more evident in adults than in prepubertal females, and it was associated with development of acyclicity. Measurement of pituitary mRNA concentrations revealed that prenatal testosterone excess induced developmental changes in gene expression of pituitary GnRH and E 2 receptors and paracrine modulators of LH and FSH synthesis in a manner consistent with subsequent amplification of LH release. Together, this series of studies suggests that prenatal testosterone excess, by its androgenic action, amplifies GnRH-induced LH response, leading to LH hypersecretion and acyclicity in adulthood, and that this programming involves developmental changes in expression of pituitary genes involved in LH and FSH release.
INTRODUCTION
Treatment of pregnant sheep with testosterone from Days 30 to 90 of the 150-day gestation period leads to reproductive dysfunction in adult female offspring [1] [2] [3] [4] [5] [6] [7] [8] . Disruptions include a progressive deterioration of estrous cycles [1] [2] [3] , development of multifollicular ovaries [4, 5] and, ultimately, infertility [1, 3] . Associated with these abnormalities is an alteration in gonadotropin secretion manifested as hypersecretion of LH but not FSH [7, 8] . Hypersecretion of LH associated with reproductive abnormalities is also evident following prenatal exposure to excess testosterone in female rhesus monkeys [9] , mice [10] , and rats [11] , and it is also seen in women with polycystic ovary syndrome [12, 13] .
Although reproductive consequences of prenatal exposure of female sheep to excess testosterone are well described, the mechanisms producing these detrimental effects are not understood. For example, it is unclear whether the selective increase in LH secretion results from androgenic action or aromatization of androgens to estrogens. In addition, prenatal testosterone treatment leads to reduced responsiveness to E 2 negative feedback, characterized by increased frequency and a tendency toward an increase in amplitude of LH pulses [8] . It is not known whether the increased LH pulse amplitude is due to heightened pituitary responsiveness to GnRH, altered amounts of GnRH or E 2 receptors, and/or changes in gonadotropin gene expression. Further, the reduced responsiveness to E 2 negative feedback in sheep exposed to excess testosterone during fetal life is evident only for LH; feedback effects of E 2 on FSH are not affected. This suggests involvement of pituitary paracrine regulators, such as activin or inhibin, and their receptors or binding proteins (e.g., follistatin).
The goal of this study was to explore mechanisms that mediate hypersecretion of LH in prenatal testosterone-treated female sheep. Our working hypothesis was that prenatal testosterone excess, by its androgenic action, amplifies GnRH-induced LH (but not FSH) secretion and, thus, hypersecretion of LH in adulthood. This increased pituitary responsiveness to GnRH results from developmental changes in GnRH and E 2 receptors, gonadotropin subunits, and paracrine factors that differentially regulate LH and FSH secretion.
MATERIALS AND METHODS

Breeding, Maintenance, and Prenatal Treatment
All procedures were approved by the Institutional Animal Care and Use Committee of the University of Michigan and were in conformity with the National Institutes of Health Guide for Use and Care of Animals. Suffolk sheep ages 2-3 yr were purchased from local farmers and were maintained in a farm inspected by the US Department of Agriculture and approved by the University of Michigan Department of Laboratory Animal Medicine. Prior to breeding, sheep were group fed with 0.5 kg shelled corn and 1 kg alfalfa hay per female sheep per day. During October to November of three successive years (2001) (2002) (2003) , ewes were mated by raddled rams. Pregnant sheep were maintained on pasture under natural photoperiods with a supplement feed of 1.25 kg alfalfa/ brome mix hay per female sheep. After birth, each mother with its lambs was individually housed for the first 3 days and then group housed in a barn under natural photoperiods except for a 60-watt bulb in the lamb feed area at night. All lambs were weaned at 8 wk and maintained in Sheep Research Facility (Ann Arbor, MI), where they were maintained outdoors and fed commercial feed pellets ad libitum.
Prenatal treatments consisted of intramuscular injections twice a week of testosterone (T1875; Sigma-Aldrich Corp., St. Louis, MO) or dihydrotestosterone (DHT) propionate (A2595-000; Steraloids Inc., Newport, RI), 100 mg in 2 ml corn oil, to pregnant sheep from Day 30 to Day 90 of gestation. Control pregnant sheep received no injections because we have found no difference in cycle dynamics of offspring born to vehicle-injected and noninjected mothers [14] .
Study 1: Pituitary Responsiveness to GnRH
This study tested the hypothesis that prenatal testosterone, via its androgenic action, increases pituitary responsiveness to GnRH and that this action is specific for LH (i.e., the FSH response is not affected). The approach was to compare pituitary responsiveness to GnRH in control females and females exposed prenatally to exogenous testosterone or DHT as well as aromatizable and nonaromatizable androgens, respectively (Fig. 1) . Only one offspring from each mother was used when twin female births were involved. Responsiveness to GnRH was tested twice, first at 5.5 wk (prepubertal), when the lambs were ovary intact, and second at 23 mo of age, after they had been ovariectomized at the end of breeding season and studied 2 mo later during the second anestrus.
Prepubertal GnRH testing involved seven control, six prenatal testosteronetreated, and five prenatal DHT-treated females. Adult testing involved five control, four prenatal testosterone-treated, and three prenatal DHT-treated females. To block pulsatile LH/GnRH release, sheep were inserted subcutaneously with one 30-mm Silastic E 2 implant [15] . Prepubertal and anestrous control females are extremely sensitive to E 2 negative feedback [16, 17] , and this E 2 treatment is known to abolish endogenous LH/GnRH pulsatility [16, 18] . Jugular blood samples (3 ml) were taken at 24-min intervals for 6 h at 1-2 wk after insertion of E 2 implants to confirm the absence of LH pulses (preGnRH bleed). GnRH (2 ng/kg; Luteinizing hormone-releasing hormone human, acetate salt L7134; Sigma, St. Louis, MO) was then administered intravenously every 90 min for 48 h via a jugular catheter. This dose of GnRH produces LH responses of magnitude similar to those seen in prepubertal females [16] . Blood samples (3 ml) were collected into heparinized tubes at 10-min intervals for 9 h (spanning six GnRH injections) beginning 42 h after initial injection for characterization of LH and FSH responses.
Study 2: Prenatal Testosterone Effects on Adult Gonadotropin Release
In view of the progressive deterioration of the reproductive axis seen in prenatal testosterone-treated females [1] [2] [3] , study 2 was performed during the second breeding season to determine whether the selective increase in LH release seen in prepubertal females in the first year of life [7, 8] persists into adulthood (second year of life). Adult control (n ¼ 6) and prenatal testosteronetreated (n ¼ 8) females (22 mo old) were given two intramuscular injections of prostaglandin F 2a (PGF 2a , 20 mg; Lutalyse; Pfizer Inc., Kalamazoo, MI) 11 days apart to induce regression of the corpora lutea, and thus synchronize the follicular phase of the cycle within a group of females (Fig. 1) . Jugular blood samples were collected at 10-min intervals from 23 to 28 h after the second PGF 2a injection for measurement of LH (all samples) and FSH (hourly samples). Twice-weekly progesterone measures were taken from the start of the second breeding season to determine whether the prenatal testosterone-treated females were cycling at the time of the experiment.
Study 3: Prenatal Testosterone Effects on Gonadotropin Subunits, GnRH Receptor, and Estrogen Receptors
Study 3 was undertaken to examine whether prenatal testosterone excess caused developmental changes in pituitary gene expression that might account for the selective increase in LH secretion and pituitary responsiveness to GnRH. For this purpose, real-time PCR was used to quantify changes in mRNA expression patterns of gonadotropin subunits (glycoprotein hormones, alpha peptide [CGA], LHB, FSHB), GnRH receptor (GNRHR), and E 2 receptors (ESR1, ESR2) at four developmental stages. Table 1 summarizes the treatments, developmental stages, and number of animals studied. Where possible, umbilical arterial levels of LH and FSH were measured to relate changes in fetal gonadotropin subunit mRNA expression with fetal LH and FSH secretion. When twin female fetuses were involved, both fetuses were studied. Values of these two female fetuses were averaged to ensure independence of individual measures in all analyses.
Pregnant ewes were anesthetized with 1000-1500 mg pentobarbital intravenously (Nembutal Na; Abbott Laboratories, Chicago, IL); anesthesia was maintained by inhalation of 1%-2% halothane (Halocarbon Laboratories, Riveredge, NJ) in oxygen-nitric oxide mixture (2:1). A midventral laparatomy was performed to expose the uterus with fetuses. Blood samples (;5 to 10 ml) were collected from umbilical arteries using a Butterfly-21 infusion set (no. 4492; Abbott Laboratories, North Chicago, IL). The ewes then were killed by a barbiturate overdose (Fatal Plus; Vortech Pharmaceuticals, Dearborn, MI), and fetuses were removed. The entire procedure took less than 30 min. The adult female sheep used in this study were the ones used in study 2; they were also killed by a barbiturate overdose. Pituitaries collected from female fetuses and adult females were frozen in liquid nitrogen and stored at À808C until real-time PCR analysis.
Study 4: Prenatal Testosterone Effects on Pituitary Paracrine Regulators of Gonadotropins
This study was undertaken to determine whether prenatal testosterone excess causes developmental changes in the mRNA expression pattern of pituitary paracrine modulators of gonadotropins that might contribute to differential changes in LH and FSH secretion and pituitary responsiveness to GnRH. Pituitary mRNA expression patterns of the following modulators were determined by real-time PCR on RNA obtained from pituitaries collected in 
Hormone Assays
Plasma concentrations of LH and FSH were measured by validated radioimmunoassays described elsewhere [19, 20] . The sensitivity (2 SDs from the buffer control) of the LH assay was 1.1 6 0.2 ng/ml of NIH-LH-S12 (n ¼ 19 assays). Mean intraassay coefficients of variation at 80% and 20% displacement points were 11.6% 6 1.4% and 5.9% 6 0.6%, respectively. The interassay coefficients of variation in three quality control pools averaging 14.4, 12.9, and 23.0 ng/ml were 4.9%, 6.2%, and 7.3%, respectively. The sensitivity of the FSH assay was 0.9 6 0.1 ng/ml of NIDDK-oFSH-1 (n ¼ 10 assays). Mean intraassay coefficients of variation at 80% and 20% displacement points were 7.5% 6 1.0% and 3.8% 6 0.7%, respectively. The interassay coefficients of variation based on two quality control pools from ovary-intact, ovariectomized ewes averaging 4.6 and 11.1 ng/ml were 10.7% and 7.9%, respectively.
Pituitary RNA Isolation and Real-Time PCR Pituitary RNA was isolated using TRIzol reagent (Invitrogen), measured by spectrophotometer or Ribogreen assay (Molecular Probes, Eugene, OR), and evaluated in a denaturing formaldehyde gel. Purification of RNA was done by DNase treatment and column clean up (Qiagen, Valencia, CA). First-strand cDNA from RNA was prepared using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) and column purified (QIAquick PCR purification kit; Qiagen). Gene-specific primers for real-time PCR (see details of primers in Table 2 ) [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] were designed using Laser gene Primer select software (DNASTAR Inc., Madison, WI) and were synthesized commercially (Invitrogen, Grand Island, NY). All cDNA samples were processed in parallel, and cycle threshold (CT) values were obtained from three replicate runs. Real-time PCR reactions (50 ll) were run in DNase-and RNase-free 96-well plates with IQ SYBR Green Supermix (Bio-Rad). The amplification conditions were: cycle 1, 958C for 30 sec; cycle 2 (353), step 1 denaturation at 958C for 30 sec, step 2 annealing at 618C (glyceraldehyde-3-phosphate dehydrogenase [GAPDH] , GNRHR, LHB, FSHB) or 558C (CGA) or 59.78C (ESR1) or 56.68C (ESR2) for 30 sec or 57.58C for 30 sec for activin series of genes (INHBB, INHA, FST, ACVR1, ACVR1B, ACVR2A, IGSF1, and TGFBR3), step 3 elongation at 728C for 30 sec (data collection and real-time analysis enabled here); cycle 3, final elongation at 728C for 5 min; and cycle 4, hold at 48C. Polymerase chain reaction product specificity was checked by melt curves and agarose gel electrophoresis. Three housekeeping genes were evaluated in this study: GAPDH, actin beta (ACTB; annealing at 57.58C), and 18S ribosomal RNA (annealing at 608C). Ratios calculated using GAPDH and ACTB as the housekeeping genes were qualitatively similar, but subtle differences were evident with 18S ribosomal RNA. Gene expression data are reported as mean fold-change in the ratio of target gene to GAPDH.
The CT values obtained for each sample were analyzed by 2 ÀDDCT method [35] . This method enables the exponential CT values to be converted into linear values of fold-change in mRNA amounts. It also enables one to remove variations in the amount of RNA used in first-strand synthesis and the amount of cDNA used for PCR. This 2 ÀDDCT method of quantification was validated by examining the efficiency of amplification of target gene and GAPDH using real-time PCR. Using reverse transcriptase, cDNA was synthesized from 1 lg total RNA isolated from a nonexperimental sheep pituitary and DNase treated before PCR. Concentrations of cDNA over a 500-fold range (1, 0.2, 0.02, and 0.002 of original cDNA) were amplified by real-time PCR using target gene and GAPDH-specific primers. The DCT (CT for target gene minus CT for GAPDH) was calculated for each cDNA dilution, and the data were fit using least-squares linear regression analysis. The slope of the regression line was 0.029, suggesting that the amplification efficiencies of target genes and GAPDH were approximately equal to two. In this experiment, the formula 2 ÀDDCT for control group was treated as 2
, such that DCT1 ¼ individual CT of GNRHR À individual CT of GAPDH, and DCT2 ¼ mean CT of GNRHR À mean CT of GAPDH of the same sample. For the treated groups, the formula was treated as 2
, such that DCT1 ¼ individual CT of GNRHR of treated sample À individual CT of GAPDH of treated sample, and DCT2 ¼ mean CT of GNRHR of control sample À mean CT of GAPDH of the control sample. 
Statistical Analyses
In study 1, differences in mean LH and FSH concentrations, LH pulse amplitudes, and LH:FSH ratios among control, prenatal testosterone-treated, and DHT-treated females were analyzed using ANOVA with Tukey adjustment for post-hoc tests. LH pulse amplitude was calculated as the mean amplitude (peak minus preceding nadir) arising from the six administered GnRH pulses from individual animals.
For study 2, LH pulses in control and prenatal testosterone-treated adults were identified using the Cluster algorithm [36] . The minimum number of points in a peak and a nadir were set at 1 and 1, respectively, and the t-statistic values used to identify a significant increase from the preceding nadir and a decrease to the following nadir were 1 and 1, respectively. Group differences in mean LH and FSH concentrations, LH pulse frequency, LH pulse amplitude, and LH:FSH ratios were analyzed using ANOVA with Tukey adjustment for post-hoc tests. LH pulse amplitude was calculated as the mean from the Cluster-identified pulses from individual animals.
For studies 3 and 4, comparison of pituitary gene expression for the different treatments was carried out on the ratio of each gene to GAPDH expression (2 ÀDDCT data). To allow comparison of the ratios across developmental ages, the ratios of target genes to GAPDH at developmental ages were calculated using the value for control at the earliest measurable time point as a calibrator in the calculations of 2 ÀDDCT . For adult samples, calculation of fold-change in gene expression was done with the control group as calibrator. The mean of three replicate ratios was first calculated for each lamb, then the lamb means were calculated, so the mother was the unit of Mean LH and FSH concentrations and amplitudes of GnRH-induced LH releases, and LH:FSH ratios in prepubertal control (C), prenatal testosterone-treated (T), and prenatal DHT-treated females. Data were analyzed by ANOVA. Asterisks indicate significant treatment differences (*P , 0.05; **P , 0.01).
analysis. Outliers (defined using Tukey criteria [37] : values greater than the 75th percentile þ 3*IQR, or less than the 25th percentile À 3*IQR) were excluded (separate analyses conducted without excluding outliers also yielded qualitatively similar results). A two-way ANOVA (allowing for unequal variances for the control and testosterone-treated animals) was used to compare the effects of treatment, age, and the treatment by age interaction for the fetal ages (gestation 65, 90, and 140 days). Post-hoc comparisons of means were carried out for specific fetal-age comparisons within each treatment and for the effect of treatment at each age. The effect of treatment on dam means at age 2 yr, after excluding outliers, was analyzed separately using independent sample t-tests. An alpha level of 0.05 was used to determine significance for all significance tests. SAS release 9.1.3 for Windows (SAS Institute Inc., Cary, NC) was used for statistical analyses.
RESULTS
Study 1: Pituitary Responsiveness to GnRH
Circulating LH and FSH patterns of three control, three prenatal testosterone-treated, and three DHT-treated lambs during the prepubertal period (ovary intact) prior to and during exogenous GnRH and composite data for all animals are presented in Figure 2 . Insertion of a 30-mm E 2 implant blocked endogenously generated LH pulses in all control and prenatal testosterone-treated females but not all prenatal DHT-treated females (only two of five blocked) during the 6-h sampling FIG. 3 . Top: Representative LH and FSH profiles of three control, prenatal testosterone-treated (T), and prenatal DHT-treated adult ovariectomized females (same animals as shown in Fig. 2) . Patterns of LH and FSH released after E 2 implant insertion are shown in panels labeled ''Pre.'' LH and FSH responses to GnRH injections given every 90 min are shown in panels labeled ''Post.'' Arrows indicate time of GnRH injections. Bottom: Mean LH and FSH concentrations and amplitudes of GnRH-induced LH releases and LH:FSH ratios in control (C), prenatal testosterone-treated (T), and prenatal DHT-treated females. Data were analyzed by ANOVA. Asterisks indicate significant treatment differences (*P , 0.05; **P , 0.01).
652 window prior to GnRH treatment. Each GnRH injection induced a pulse of LH in all animals (Fig. 2) . Compared with control females, the resulting mean LH concentration was higher in prenatal testosterone-treated and prenatal DHTtreated females (one prenatal testosterone-treated lamb did not respond and was not included in this analysis; P , 0.05) compared with that of the control group. LH pulse amplitudes (ng/ml) also were significantly higher in prenatal testosteronetreated (P , 0.05) and prenatal DHT-treated females (P , 0.01) compared with control females. Mean circulating FSH concentration did not differ among groups, and FSH amplitudes were not calculated due to ambiguity in defining FSH pulses. Mean LH:FSH ratios also were higher in prenatal testosterone-treated (P , 0.01) and DHT-treated (P , 0.01) groups compared with the control group. Figure 3 depicts results prior to and during the GnRH challenge in these same animals during adulthood (ovariectomized). Treatment with E 2 blocked LH pulses in all control, three of four prenatal testosterone-treated, and two of three prenatal DHT-treated females during the 6-h sampling window prior to GnRH challenge. Each GnRH injection induced an LH response in all females (Fig. 3, post) . Mean LH concentration was higher in prenatal testosterone-treated females (P , 0.01) but not in prenatal DHT-treated females. LH pulse amplitudes were significantly higher (P , 0.01) in prenatal testosteronetreated females. In spite of the small number of animals studied, LH pulse amplitudes tended to be higher (P ¼ 0.07) in prenatal DHT-treated females compared with control females. Mean circulating FSH concentration did not differ among the three groups. Mean LH:FSH ratio was higher in prenatal testosterone-treated group (P , 0.01), but not the prenatal DHT-treated group, compared with the control group.
Study 2: Prenatal Testosterone Effects on Adult Gonadotropin Release
Twice-weekly progesterone measures preceding the study found that five of the eight prenatal testosterone-treated females were not cycling at the time of the study. LH and FSH profiles from four each of the adult ovary-intact control and prenatal testosterone-treated females, mean LH and FSH concentrations, LH pulse amplitude, and LH:FSH ratios of the two treatment
testosterone (T)-treated adult females. Closed circles depict peaks of pulses identified by the Cluster analysis [36] . Bottom: Mean LH concentration, LH pulse frequency, LH pulse amplitude, mean FSH concentration, and LH:FSH ratios in adult control (open bars, C) and prenatal testosterone (T)-treated females (closed bars summarize results for the entire group, shaded bars for the cycling group, and hatched bars for the acyclic group). Data were analyzed by ANOVA. Asterisks indicate significant treatment differences (*P , 0.05; **P , 0.01).
PRENATAL PROGRAMMING OF GONADOTROPIN REGULATION groups are shown in Figure 4 . When all animals were included in the analysis, the mean LH concentration was higher (P , 0.01), and the mean LH pulse amplitude tended to increase (P ¼ 0.07) in prenatal testosterone-treated females, but there was no group difference in pulse frequency (P . 0.05). LH:FSH ratio also was significantly higher in prenatal testosterone-treated females compared with control females (P , 0.05).
Because five of the eight prenatal testosterone-treated females were not cycling at the time of study, separate analyses also were carried out to compare values in cyclic vs. acyclic prenatal testosterone-treated females with those of controls. The mean LH concentration and LH pulse amplitude were significantly higher in the acyclic prenatal testosteronetreated females compared with controls (Fig. 4) . These group differences were not observed for prenatal testosterone-treated females that expressed estrous cycles at the time of the study. There were no differences among pulse frequencies of control, cycling prenatal testosterone-treated, or acyclic prenatal testosterone-treated groups. Mean FSH concentrations showed a trend for an increase in both acyclic and cyclic prenatal testosterone-treated females. LH:FSH ratios tended to be higher in acyclic testosterone females (P ¼ 0.06) but not in cyclic testosterone females compared with control females.
Study 3: Prenatal Testosterone Effects on Gonadotropin Subunit, GnRH Receptor, and E 2 Receptors
Ratios of pituitary mRNA expression of CGA, LHB, FSHB, GNRHR, ESR1, and ESR2 with that of GAPDH from control and prenatal testosterone-treated female fetuses (Days 65, 90, and 140) are presented in Figure 5 . All three gonadotropin subunit mRNAs were influenced by age and treatment (Fig. 5,  top ). There were significant age (P , 0.01), treatment (P , 0.05), and age by treatment (P , 0.05) effects with CGA mRNA expression. CGA mRNA expression did not differ between Fetal Days 65 and 90 but increased from Days 90-140 in both control and prenatal testosterone-treated fetuses (control: P , 0.01; testosterone: P , 0.05). Prenatal testosterone excess reduced CGA mRNA expression significantly at Fetal Day 140 (P , 0.05) compared with control fetuses, but not at other fetal ages. A significant age effect (P , 0.05) was evident with LHB mRNA. Prenatal testosterone excess reduced the expression of LHB mRNA at Fetal Days 65 (P , 0.005) and 90 (P , 0.05) but not Day 140. There was also a significant age (P , 0.005), treatment (P , 0.05), and age by treatment (P , 0.05) effect in the expression patterns of FSHB mRNA. FSHB mRNA expression decreased from Day 65 to Day 90 in both control and prenatal testosterone-treated fetuses (control: P , 0.005; prenatal testosterone-treated: P , 0.01), increasing thereafter from Day 90 to Day 140 in both groups (control: P , 0.05; prenatal testosterone-treated: P , 0.01). Prenatal testosterone treatment increased FSHB mRNA expression in Day 65 fetuses (P , 0.05) but decreased (P , 0.05) it in Day 90 fetuses.
Gonadotropin-releasing hormone and E 2 receptor mRNAs are presented in Figure 5 (bottom panels). GNRHR mRNA was not detectable on Fetal Days 65 and 90 (except in two prenatal testosterone-treated fetuses at Day 90). GNRHR mRNA tended to be higher in prenatal testosterone-treated females compared with controls (P ¼ 0.095) at Fetal Day 140. There was a significant age (P , 0.005), treatment (P , 0.001), and age by treatment interaction (P , 0.01) with ESR1 but not ESR2 mRNA expression. ESR1 mRNA expression was the highest on Fetal Day 65 and declined from Fetal Day 65 to Day 90 (P , 0.001) and from Day 90 to Day 140 (P , 0.05) in control fetuses. There was no age effect on ESR1 mRNA expression in prenatal testosterone-treated females. Expression of ESR1 mRNA was lower in prenatal testosterone-treated vs. control fetuses on Fetal Day 65 (P , 0.05), with a tendency toward a decline also on Fetal Day 90 (P ¼ 0.066).
Circulating Levels of LH and FSH
Presence of fibrin in samples prevented accurate assessment of LH and FSH from Fetal Day 65 and Fetal Day 90 samples, and hence is not reported. Both LH and FSH measures were available from only four control and five prenatal testosteronetreated Day 140 female fetuses. The mean LH concentrations in umbilical arterial blood of Day 140 female fetuses averaged 3.3 6 1.2 and 5.9 6 4.8 ng/ml, respectively, for control and prenatal testosterone-treated groups. Corresponding mean FSH values were 2.4 6 0.6 and 3.1 6 1.4 ng/ml, respectively. The ratio of LH:FSH for this subset of prenatal testosterone-treated females was numerically higher (5.5 6 2.2) than controls (1.1 6 0.4) but did not differ significantly (P ¼ 0.12).
Study 4: Prenatal Testosterone Effects on Pituitary Paracrine Regulators of Gonadotropins
Developmental changes in expression of mRNA for LH and FSH modulators at Days 65, 90, and 140 are shown in Figure 6 .
Inhibin and activin. A significant age effect (P , 0.01) and a tendency toward a treatment (P ¼ 0.078) effect were evident with INHA mRNA expression (Fig. 6, top left) . INHA mRNA decreased from Fetal Day 65 to Day 90 in both control (P , 0.01) and prenatal testosterone-treated (P , 0.01) fetuses, but did not decrease from Day 90 to Day 140. Prenatal testosterone treatment tended to decrease INHA mRNA expression in Fetal Day 65 (P ¼ 0.058) but not in other fetal ages. Inhibin beta A (INHBA) mRNA was not detected in sheep pituitary at any age studied (not shown). In terms of INHBB, a significant age (P , 0.01) and age by treatment effect (P , 0.05) was evident. INHBB mRNA expression decreased from Fetal Day 65 to Day 90 in both control (P , 0.001) and prenatal testosterone-treated (P , 0.01) fetuses. This expression increased from Fetal Day 90 to Day 140 in prenatal testosterone-treated (P , 0.01) but not in control fetuses. Prenatal testosterone treatment reduced INHBB mRNA expression on Fetal Day 90 (P , 0.05) but increased (P , 0.05) this expression on Fetal Day 140 compared with controls.
Inhibin/activin binding proteins. Prenatal testosterone excess also altered the developmental expression of binding proteins of activin and inhibin. There was an age (P ,0.001) and an age by treatment (P , 0.05) effect in FST mRNA expression. Expression was lower in Day 140 compared with Day 90 control fetuses (P , 0.001), and a tendency toward a similar decline was also evident in prenatal testosterone-treated (P ¼ 0.061) fetuses. However, FST mRNA expression was higher in Day 140 prenatal testosterone-treated fetuses compared with age-matched control fetuses (P , 0.001). An age effect (P , 0.01) and a tendency for treatment effect (P ¼ 0.097) was evident with mRNA expression of the inhibin binding protein IGSF1. IGSF1 mRNA expression increased from Fetal Day 65 to Day 90 in both control (P , 0.005) and prenatal testosterone-treated (P , 0.05) fetuses, declining to Day 65 levels in both control (P , 0.005) and prenatal testosterone-treated (P , 0.05) Day 140 fetuses. There was no treatment effect of prenatal testosterone excess on IGSF1 mRNA expression during any of the fetal ages studied. A tendency toward an age effect (P ¼ 0.08) and a significant age by treatment effect (P , 0.005) was evident in the expression of TGFBR3 mRNA (also known as betaglycan). TGFBR3 mRNA expression declined from Day 65 to Day 90 in control (P , 0.005) but not in prenatal testosterone-treated fetuses. TGFBR3 mRNA expression was lower in prenatal testosteronetreated females at Fetal Day 65 compared with controls (P , 0.005) but did not differ across other fetal ages.
Activin receptors. A prenatal testosterone treatment effect was observed in two of the three activin receptor mRNAs measured. Overall analyses revealed no age, treatment, or age by treatment effect with ACVR1 mRNA expression. An age effect of ACVR1B mRNA was evident in that it was detectable on Fetal Days 90 and 140 but not Day 65. Prenatal testosterone excess increased (P , 0.05) ACVR1B mRNA expression on Fetal Day 140 compared with controls. A significant age (P , 0.05) and age by treatment (P , 0.05) effect was also evident with ACVR2A mRNA expression. ACVR2A mRNA was first detectable on Fetal Day 90. ACVR2A expression level was higher (P , 0.01) in Day 90 prenatal testosterone-treated fetuses compared with Day 140 fetuses. Prenatal testosterone treatment increased (P , 0.05) ACVR2A mRNA expression in Day 90 fetuses.
Prenatal Testosterone Effects on Adult Pituitary mRNA Expression
Pituitary expression of all of the above regulators in pituitaries collected from adults is shown in Figure 7 . Prenatal testosterone treatment increased CGA and ACVR1 mRNA expression (P , 0.05) but had no effect on expression of all other mRNAs.
DISCUSSION
This study documents that prenatal testosterone treatment, by its androgenic action, increases pituitary responsiveness to GnRH, thus contributing at least in part to the LH hypersecretion in prepubertal and adult prenatal testosteronetreated females and, possibly, loss of cyclicity in adulthood. Furthermore, prenatal testosterone treatment induced developmental changes in mRNA expression of GnRHR and ESR1, a regulator of pituitary sensitivity to E 2 negative feedback [38] , as well as paracrine factors involved in the differential control of LH and FSH release in a manner consistent with predicted changes in LH/FSH production/release. These results are discussed below relative to the four study objectives.
Study 1: Pituitary Responsiveness to GnRH
We first determined whether increased pituitary responsiveness to GnRH contributes to the selective LH hypersecretion seen in prenatal testosterone-treated peripubertal females [7, 8] and if it is programmed via the androgenic actions of testosterone. Increased GnRH-induced LH but not FSH release in both ovary-intact prepubertal and ovariectomized adult prenatal testosterone-treated females after suppression of endogenous LH pulses by a constant-release E 2 implant provides evidence that increased pituitary responsiveness to GnRH contributes to selective LH hypersecretion later in life. Our similar findings in females exposed prenatally to excess DHT suggests that this amplification of responsiveness to GnRH results from the androgenic actions of testosterone.
Although androgen receptors are present in pituitary [39] for testosterone to exert its effect, the extent to which the increased LH responsiveness to GnRH seen in prenatal DHT-treated females is the result of direct pituitary effect as opposed to the added contribution from endogenous GnRH is unclear. Unfortunately, the 30-mm E 2 implant did not completely suppress LH pulses in many prenatal DHT-treated females. Nonetheless, the low frequency of LH pulses during the preGnRH treatment period in concert with the similar magnitude of LH responses to sequential administration of GnRH suggests that the contribution from endogenous GnRH, if any, is likely to be little. It is interesting to note that increased pituitary responsiveness to GnRH also appears to contribute to LH hypersecretion in prenatal testosterone-treated monkeys [9] and in women with PCOS [12, 13, [40] [41] [42] . A limitation of all of those studies, however, is that endogenous GnRH action was not blocked prior to testing with GnRH; thus, increased GnRH secretion prior to GnRH challenge as opposed to the intrinsic responsiveness of the pituitary itself could have contributed to the increased responsiveness to GnRH. The present work with prenatal testosterone-treated sheep overcomes this limitation.
Study 2: Prenatal Testosterone Effects on Adult Gonadotropin Release
The foregoing observations of increased responsiveness to GnRH specific to heightened LH release fit nicely with the second study, which determined that LH hypersecretion persisted into adulthood and was associated with a disruption of estrous cyclicity in prenatal testosterone-treated females. We previously found that LH secretion was heightened in prenatal testosterone-treated prepubertal females, and this effect was more pronounced at 24 wk than at 12 wk [8] . This evidence for a progressive deterioration is in accord with our present finding; the magnitude of LH increase seen in adult prenatal testosterone-treated females (in this study) was several-fold higher than that seen in prepubertal lambs [8] ; animals used in this study are an independent sample set from the same testosterone-treated breeding cohort used in our earlier prepubertal studies [8] .
Relative to this, the mixed physiologic status of the prenatal testosterone-treated females in this study is especially interesting in that it is consistent with a progressive development of reproductive abnormalities as a consequence of prenatal programming. Analyses of the cycling and acyclic prenatal testosterone-treated groups separately revealed significant LH hypersecretion only in the acyclic females; LH values in the cyclic prenatal testosterone-treated females were intermediate between control and acyclic prenatal testosterone-treated females. Collectively, these findings are consistent with progressive amplification of LH hypersecretion and progressive loss of cyclicity [2, 3] . At the time of testing in the second year of life, the group comprised both cycling (36%) and acyclic (64%) females. Although differences in cycle status of these animals may reflect differences in fetal susceptibility to testosterone exposure or absolute levels of testosterone reaching the fetus, an intriguing possibility is that all of the animals would be acyclic if studied at a later age.
While changes in mean LH and pulse amplitude were evident in prenatal testosterone-treated females who had reached adulthood, contrary to our expectation, no differences were seen in LH pulse frequency. One caveat in interpreting these findings is that the sampling frequency of 10 min may have been inadequate to assess frequency accurately. Fiveminute sampling has been used to estimate high-frequency LH pulses characterizing the late follicular phase of the cycle [43] . A second caveat in interpreting the lack of an effect on frequency may relate to when LH pulses were examined relative to onset of LH surge. We have observed a delayed onset of LH surge in prenatal testosterone-treated females [7] , and thus the LH pulse analysis in the present study would have been at a relatively earlier time point in follicular phase in prenatal testosterone-treated females. Despite these caveats, the collective results of studies 1 and 2 provide important insight into the reproductive consequences of prenatal testosterone treatment by showing a progressive loss of cycles associated with LH hypersecretion and enhanced pituitary responsiveness to GnRH.
Study 3: Prenatal Testosterone Effects on Gonadotropin Subunit, GnRH Receptor, and E 2 Receptors
The third objective of this study was to determine whether developmental changes in expression patterns of gonadotropin subunits and GnRH/E 2 receptors induced by fetal testosterone excess set the stage for subsequent LH amplification. During normal ontogeny, serum LH concentrations are higher in female than in male fetuses between Days 55 and 100 of gestation [44, 45] . Although LH concentrations in Day 70 to Day 90 ovine female fetuses are reported to be high, falling progressively as gestation advanced, LH concentrations in male fetuses follow the opposite trend: low before 90 days but gradually increasing from Day 90 to Day 130 of gestation [45] . This sex difference in fetal LH levels was attributed to the early increase in testosterone (negative feedback) in male fetuses [46] [47] [48] . Similar characterization has not been undertaken at the mRNA level. Assuming that changes in LHB mRNA reflect changes in circulating LH, the prediction would be that the early increase in testosterone in prenatal testosterone-treated females (administered) would result in lower LHB mRNA levels in Day 65 and Day 90 fetuses. Findings from this study of reduced levels of LHB mRNA in Day 65 and Day 90 prenatal testosterone-treated fetuses compared with control fetuses support this prediction. Increases in LHB mRNA in Day 140 relative to Day 90 prenatal testosterone-treated fetuses are consistent with the LH increase reported in males. However, LHB mRNA or LH concentrations in Day 140 prenatal testosterone fetuses did not differ significantly from control fetuses of similar age (although there was a trend toward numerical increase in LH). A previous study found that prenatal testosterone excess induced an increase in LH pulse frequency at this time point [48] . Since LH is released in a pulsatile manner, the single time point measure of fetal LH and PRENATAL PROGRAMMING OF GONADOTROPIN REGULATION the small sample size in the current study may have masked the LH increase. The high variability in LH levels seen at this time supports this premise. Analogous to this, the increased LH pulse frequency seen in prenatal testosterone-treated females at 12 wk was not reflected in the mean LH levels [8] . Variability in LHB mRNA levels may also be reflective of the time when pituitary was collected relative to an LH pulse, as rapid changes in pituitary mRNA have been reported [49, 50] .
Increases in GNRHR mRNA expression seen in prenatal testosterone-treated Day 140 fetuses (not detectable at Days 65 and 90) are also supportive of an increase in LH release. Because E 2 infusion during gestation suppresses LH in control female fetuses [51] , and increased LH secretion in prenatal testosteronetreated sheep involves decreased pituitary responsiveness to E 2 [8] , we predicted E 2 receptor mRNA levels would be lower in prenatal testosterone-treated females. Our findings of decline in ESR1 mRNA expression at Days 65 and 90 are consistent with this premise. The absence of changes in ESR2 mRNA expression is consistent with the premise that ESR1 but not ESR2 is involved in negative feedback regulation of LH [38, 52] .
Study 4: Prenatal Testosterone Effects on Pituitary Paracrine Regulators of Gonadotropins
Like LH, there are also sex differences in plasma FSH concentrations in ovine fetuses, possibly stemming from the early testosterone feedback [46] [47] [48] in the males. In general, in contrast to LH levels being low, circulating concentrations of FSH are higher in females than males from Gestational Days 71-150 [45, 53] . Gonadectomy before Day 130 increased mean FSH concentrations and LH pulse frequency in males but not in females [54, 55] . Furthermore, maternal passive immunization against GnRH caused a suppression of both LH and FSH secretion in males, but only LH in the females [56] . Findings from this study also show that prenatal testosterone treatment, while having similar suppressive effects on Day 90 LHB and FSHB mRNA, had opposing effects on LHB and FSHB mRNA in Day 65 fetuses, which was reflected as a reduction in LHB mRNA and increase in FSHB mRNA. Reported differences in developmental regulation of LH and FSH in males and females following gonadectomy [54, 55] and the differential effects of prenatal testosterone treatment on LHB and FSHB mRNA observed in this study suggest involvement of other selective pituitary modulators of LH and FSH.
If paracrine changes account for differential release of LH and FSH in prenatal testosterone-treated females, higher expression of negative regulators of FSH (INHA, FST, TGFBR3, IGSF1) or lower expression of positive regulators of FSH (INHBB, ACVR1, ACVR1B, and ACVR2A) would accompany or precede reduced FSHB mRNA or protein expression, and the opposite would be true with increased FSHB mRNA or protein expression. This premise held true for the most part. A decrease in mRNA of INHA and TGFBR3, an inhibin co-receptor that increases affinity of inhibin to bind activin receptors and mediates functional antagonism of activin signaling [57] , was evident at Day 65 prenatal testosteronetreated fetuses, a time point at which an increase in FSHB mRNA was evident. Furthermore, because in vitro studies in sheep find inhibin and activin to have opposite effects on LH from that of FSH, with inhibin increasing LH and activin suppressing LH [58, 59] , the reduced expression of TGFBR3 in d65 prenatal testosterone-treated fetuses may lead to reduction in activin antagonism, thus contributing toward the differential effects of prenatal testosterone treatment on LHB (decrease) and FSHB (increase) mRNA. Similarly, because activins initiate downstream signaling events by sequentially interacting The effects of prenatal testosterone excess on LHB and FSHB mRNA expression. D) Reported differences in circulating LH/FSH between male and female fetuses (male fetuses differ from females in that they, like the prenatal testosterone-treated females, are exposed to an early increase in testosterone from the developing testes). Known effects of each gene on LH and FSH and the direction of prenatal testosterone-induced changes in mRNA expression are indicated as À, þ, or closed triangles (see key in shaded area). The predicted effect of these changes on LHB and FSHB mRNA expression in prenatal testosterone-treated females (T) relative to controls (C) is provided in the bottom of each panel.
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with ACVR2A and the type I receptor [60, 61] , the increase in ACVR2A mRNA at Fetal Day 90 and ACVR1B mRNA at Fetal Day 140 should provide a stimulatory input to FSH and an inhibitory input to LH. However, the effects of increase in activin and activin receptor expression on LH and FSH in the Day 140 female fetuses appear to be counterbalanced by increased expression of FST, a neutralizer of activin action.
Our findings provide evidence that prenatal testosterone excess induces changes in the developmental progression of various regulatory signals, the sum effect of which directs differential expression of LH and FSH. Figure 8 summarizes changes in key integrators of hypothalamic and ovarian inputs (GNRHR and ESR1) and pituitary paracrine mediators and the predicted stimulatory or inhibitory input to LH and FSH at Fetal Days 65, 90, and 140. While the reduction in ESR1 on Fetal Day 65 is likely to reduce E 2 negative feedback input to LH, increase in pituitary activin action stemming from a reduction in INHA and TGFBR3 may override the positive effects of reduced ESR1, resulting in reduced expression of LHB mRNA and increased expression of FSHB mRNA. Similarly, an increase in the ACVR2A mRNA expression and consequent increase in activin action A may override the effects of reduced ESR1 mRNA at Fetal Day 90, resulting in reduced LHB mRNA expression. The increase in pituitary GNRHR mRNA expression at Fetal Day 140 may contribute toward the postnatal amplification of LH release [7, 8] . An increase in FST, neutralizer of activin action, stemming from an increase in FST mRNA expression may negate the potential for increased activin action stemming from increased INHBB and ACVR1B mRNA expression. Changes in LHB and FSHB mRNA expression seen in this study parallel reported changes in circulating LH/FSH of male fetuses (Fig. 8D , open triangles) [44, 45, 53] and the prenatal testosterone-treated female fetuses studied at one time point [48] . They are also consistent with the observed changes in expression of the various modulators, suggesting that the developmental integration of these regulatory signals likely sets the stage for the subsequent increase in LH release seen during postnatal life [8] .
Prenatal Testosterone Programming of Genes Involved in Gonadotropin Biosynthesis in Adult Females
Since the regulation of gonadotropin secretion in adult females can be influenced by the cycle stage, the relationships between gonadotropin changes and relevant subunit mRNAs are discussed here separately from developmental changes in fetuses discussed earlier. Clearly, the cycling prenatal testosterone-treated females during the presumptive follicular phase showed increased LH and not FSH secretion. No changes in mRNA expression patterns of GNRHR or ESR1 were evident, consistent with lack of changes in LHB and FSHB mRNA expression. The only increase seen-namely, that of ACVR1 mRNA-is inconsistent with observed changes in LHB and FSHB mRNA expression. As such, the increased LH release seen in the adult animals must involve posttranscriptional events either at the translational (change in mRNA translational efficiency) or posttranslational levels (i.e., GNRHR and ESR1, receptor recycling, or degradation).
In summary, prenatal testosterone treatment in sheep, by its androgenic action, programs increased pituitary responsiveness and produces pronounced increase in LH secretion in adults. Furthermore, prenatal testosterone treatment alters developmental trajectory of pituitary mediators of gonadotropins in a manner consistent with the role they play in differential regulation of LH and FSH, the observed changes in LHB and FSHB mRNA expression, and/or the expected pattern of gonadotropin release.
